databas
nationwid
sar
databas
taiwan
includ
laboratoryconfirm
case
sar
report
march
june
detail
data
compil
describ
elsewher
analysi
focus
initi
nasopharyng
sarscov
load
time
admiss
hospit
includ
patient
whose
viru
load
quantifi
use
commerci
avail
rtpcr
assay
artu
real
art
hpacoronaviru
artu
well
patient
success
neg
result
test
nasopharyng
sampl
diagnos
sar
base
posit
find
seroconvers
sarsneutr
antibodi
genet
studi
genet
studi
design
compar
genet
background
patient
sar
without
detect
nasopharyng
sarscov
surviv
patient
sar
follow
genet
unrel
patient
laboratoryconfirm
sar
consent
particip
studi
refer
group
taiwanes
subject
select
basi
age
sexstratifi
random
sampl
scheme
biobank
compil
part
nationwid
popul
studi
enrol
han
chines
descend
resid
taiwan
studi
protocol
includ
inform
consent
statement
conform
fifth
edit
helsinki
declar
approv
medic
research
ethic
committe
institut
biomed
scienc
taipei
taiwan
applic
gene
singlenucleotid
polymorph
snp
select
focus
gene
whose
product
either
known
predict
interact
sarscov
antivir
respons
inflamm
immunostimul
tabl
snp
gene
identifi
databas
snp
consortium
nation
center
biotechnolog
inform
genesnp
public
internet
resourc
genecard
japan
snp
databas
total
snp
gene
tabl
studi
snp
show
variant
accord
result
test
run
dna
select
refer
han
popul
power
snp
genotyp
genotyp
perform
use
either
sequenom
massarray
malditof
system
sequenom
taiwan
nation
genotyp
center
core
facil
use
primer
snp
type
design
use
spectrodesign
softwar
sequenom
abi
system
appli
biosystem
sequenom
system
could
design
primer
qualiti
control
genotyp
sampl
repeat
discrep
verifi
sequenc
analysi
error
rate
statist
analysi
data
analysi
perform
unless
state
otherwis
use
sa
version
sasgenet
sa
institut
hardyweinberg
equilibrium
test
snp
result
han
refer
popul
genotyp
assay
repeat
anoth
method
use
test
result
violat
hardyweinberg
equilibrium
haplotyp
snp
gene
predict
use
phase
program
snp
univari
analysi
perform
compar
frequenc
allel
genotyp
patient
without
detect
sarscov
nasopharyng
specimen
test
model
dominantrecess
codomin
trait
perform
identifi
suscept
genotyp
snp
empir
p
valu
calcul
use
permut
test
round
snp
associ
viru
load
demonstr
test
signific
perform
includ
test
cochranarmitag
trend
test
fisher
exact
test
exact
mantelhaenszel
test
continu
variabl
ie
age
viru
load
compar
use
wilcoxon
rank
sum
test
analyz
factor
could
potenti
affect
viru
load
includ
demograph
characterist
sourc
infect
durat
ill
associ
nasopharyng
sarscov
shed
multipl
variabl
analyz
simultan
cumul
logist
model
interact
gene
test
cumul
logist
model
viru
detect
nasopharyng
sarscov
load
viru
load
respiratori
tract
time
admiss
hospit
diagnosi
sar
rang
wide
undetect
sarscov
rna
copiesml
figur
although
longitudin
studi
patient
sar
indic
nasopharyng
viru
load
increas
fifth
day
ill
decreas
day
ill
viru
load
time
admiss
patient
sar
data
set
reflect
trend
rise
fall
occur
first
week
clinic
cours
sar
rather
given
day
within
first
week
clinic
cours
sar
nasopharyng
viru
load
differ
patient
rang
wide
overal
patient
sar
undetect
level
nasopharyng
viru
shed
lack
detect
viru
correl
time
specimen
collect
success
sampl
obtain
patient
test
result
specimen
remain
neg
factor
influenc
level
viru
shed
among
patient
sar
undetect
level
nasopharyng
sarscov
shed
found
often
among
femal
patient
among
male
patient
also
found
often
among
younger
patient
patient
year
age
among
older
patient
patient
year
age
tabl
figur
viru
titer
patient
detect
viru
shed
focu
investig
femal
patient
consist
shed
lower
titer
viru
male
patient
p
multivari
logist
regress
model
furthermor
multivari
cumul
logist
regress
model
date
sampl
collect
control
underli
diseas
sourc
infect
identifi
consid
simultan
femal
sex
p
younger
age
p
independ
associ
lower
viru
load
wherea
underli
diseas
known
sourc
infect
influenc
viru
shed
lack
viru
detect
may
result
lower
level
viru
shed
occur
time
sampl
collect
earli
day
ill
later
day
ill
clinic
phase
diseas
multivari
model
confirm
nasopharyng
specimen
level
viru
shed
undetect
collect
time
rel
diseas
onset
specimen
viru
level
detect
lack
detect
viru
correl
earli
sampl
collect
clinic
signific
viru
shed
analyz
mortal
rate
rel
level
viru
shed
valid
biolog
signific
detect
viru
nasopharyng
specimen
tabl
mortal
rate
among
patient
sarscov
rna
copiesml
detect
nasopharyng
specimen
wherea
mortal
rate
among
patient
undetect
level
viru
nasopharyng
specimen
furthermor
durat
surviv
patient
whose
case
sar
fatal
significantli
shorten
week
increas
level
viru
shed
occur
acut
phase
diseas
tabl
patient
fatal
case
sar
sarscov
rna
copiesml
detect
nasopharyng
specimen
die
within
first
week
sar
ill
wherea
patient
fatal
case
sar
viru
detect
nasopharyng
specimen
die
within
first
week
ill
p
cochranarmitag
trend
test
polymorph
gene
associ
detect
sarscov
nasopharyng
specimen
mortal
data
valid
biolog
signific
undetect
nasopharyng
viru
shed
compar
genotyp
distribut
snp
group
patient
detect
undetect
viru
shed
tabl
figur
snp
test
snp
gene
show
signific
associ
viru
load
promot
upstream
atg
relb
reticuloendotheliosi
viral
oncogen
homolog
b
intron
atg
fibrinogenlik
protein
result
amino
acid
substitut
glycin
glutam
acid
overrepres
patient
detect
level
sarscov
genotyp
distribut
snp
empir
p
valu
calcul
use
permut
test
round
confirm
statist
signific
p
tabl
analysi
perform
stratif
gene
suggest
interact
gene
contribut
level
viru
shed
multivari
analysi
confirm
loci
independ
associ
viru
load
tabl
furthermor
homozyg
individu
possess
allel
increas
risk
viru
shed
compar
heterozyg
individu
possess
allel
genotyp
allel
control
total
snp
gene
type
polymorph
found
loci
relb
loci
locu
loci
haplotyp
analyz
singl
locu
show
associ
viru
load
compar
allel
genotyp
distribut
loci
patient
sar
healthi
taiwanes
refer
group
found
statist
differ
tabl
clinic
signific
viru
burden
intuit
difficult
directli
demonstr
present
report
show
dramat
interindividu
differ
viru
burden
direct
correl
viru
burden
clinic
outcom
analysi
indic
high
sarscov
load
associ
earli
death
addit
high
mortal
rate
previous
report
elsewher
therefor
result
suggest
level
nasopharyng
viru
shed
acut
phase
sar
week
ill
monitor
index
therapeut
clinic
progress
identif
gene
associ
viru
load
potenti
provid
lead
pathway
involv
viru
clearanc
earli
phase
infect
best
knowledg
first
studi
probe
factor
influenc
sarscov
load
exploratori
natur
genet
studi
necessit
screen
larg
number
snp
appli
convent
bonferroni
correct
multipl
test
n
would
appropri
howev
intern
valid
result
base
small
sampl
size
epidem
set
substanti
result
permut
test
basi
preset
level
statist
signific
snp
singl
analysi
discuss
addit
snp
gene
show
differ
allel
frequenc
patient
without
detect
sarscov
differ
reach
level
consid
signific
figur
also
highlight
investig
opportun
aris
candid
gene
select
basi
biolog
plausibl
innat
immun
respons
viral
infect
broad
sens
rather
specif
sarscov
thu
similar
consider
may
pertin
applic
potenti
influenza
pandem
individu
preexist
immun
effect
innat
immun
host
would
conspicu
three
snp
relb
belong
proinflammatori
gene
signal
pathway
involv
transcript
factor
sever
proinflamm
pathway
converg
relb
subunit
relb
belong
rel
protein
evolutionarili
conserv
mediat
immun
respons
especi
import
cytokin
express
differenti
surviv
cell
immun
system
relb
mutant
mice
display
sever
fatal
multiorgan
inflamm
induct
relb
subunit
reduc
lymphocyt
old
mice
potenti
mechan
explain
senesc
immun
whether
genet
variant
relb
associ
higher
viru
load
repres
suppress
overli
reactiv
function
relb
ie
inflamm
signal
remain
elus
member
famili
also
pleiotrop
proinflammatori
cytokin
activ
natur
killer
cell
enhanc
helper
type
cell
immun
respons
constitut
express
lung
knockout
mice
shown
clear
influenza
viru
effect
polymorph
allel
report
predict
control
plasma
viremia
patient
infect
undergo
antiretrovir
therapi
suggest
particip
clearanc
viral
infect
broad
sens
estrogen
shown
reduc
mrna
level
mous
uteru
suggest
regul
express
could
sex
depend
outcom
infect
level
respons
vaccin
note
demonstr
sex
differ
see
beagley
et
al
moralesmontor
et
al
review
innat
adapt
immun
may
regul
sex
hormon
higher
mortal
rate
among
male
patient
sar
suggest
analysi
hong
kong
taiwan
databas
would
inform
analysi
includ
inform
nasopharyng
viru
burden
current
commonli
use
method
diagnos
sar
viral
infect
protein
express
lymphocyt
macrophag
endothelium
prothrombinas
report
contribut
fibrin
deposit
viral
hepat
express
associ
number
patholog
condit
inclus
present
studi
base
report
express
could
induc
nucleocapsid
protein
virul
mous
hepat
viru
also
coronaviru
snp
also
show
associ
clinic
sever
sar
wy
tsai
csjf
wjc
vo
cck
ymac
yt
lu
cl
liu
cl
chao
hlc
hwk
bl
chiang
fl
ij
su
msh
unpublish
data
protein
highli
express
respiratori
tract
accord
find
immunohistochem
analysi
ml
huang
ly
chao
msh
unpublish
data
human
mrna
shown
preferenti
express
memori
lymphocyt
one
studi
patient
sar
advanc
age
higher
mortal
rate
higher
viru
load
younger
patient
studi
observ
relat
preferenti
express
memori
lymphocyt
remain
investig
patient
highest
level
viru
shed
sarscov
rna
copiesml
includ
genet
analysi
earli
death
therefor
possibl
conduct
multivari
analysi
simultan
examin
effect
age
sex
genet
polymorph
death
biolog
basi
increas
viru
load
older
patient
remain
elus
senesc
immun
see
stout
suttl
review
undermin
efficaci
innat
adapt
immun
enhanc
viru
infect
age
confound
han
descend
constitut
popul
taiwan
genet
homogen
accord
recent
studi
snp
major
histocompat
complex
popul
stratif
confound
result
major
concern
furthermor
work
constitut
populationbas
studi
surviv
patient
sar
solicit
select
bia
involv
classif
particip
patient
sar
case
control
group
base
result
test
determin
viru
burden
conclus
sarscov
load
initi
phase
infect
crucial
clinic
outcom
patient
sar
shown
believ
first
time
associ
polymorph
gene
involv
innat
immun
gene
although
claim
comprehens
list
exemplifi
potenti
pathway
innat
immun
respons
sarscov
broadli
viral
infect
imper
proceed
function
studi
test
whether
gene
inde
function
activ
signal
pathway
direct
suppress
viru
replic
clearanc
viral
infect
cell
understand
interplay
viru
load
earli
stage
week
ill
later
stage
week
ill
host
respons
might
contribut
clinic
outcom
sar
help
clinic
manag
patient
sar
